Hamid Erfanian - 23 Nov 2022 Form 4 Insider Report for ENZO BIOCHEM INC (ENZB)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ENZB
Reported as of: 23 Nov 2022
Net transaction value: +$197,000
SEC form: 4
Accepted by SEC: 28 Nov 2022, 17:27:58 UTC
Prior SEC filing: 17 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Hamid Erfanian

Key filing fact

Hamid Erfanian filed Form 4 for ENZO BIOCHEM INC (ENZB) on 28 Nov 2022.

Key facts

This page summarizes Hamid Erfanian's Form 4 filing for ENZO BIOCHEM INC (ENZB).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 28 Nov 2022, 17:27.

Change

Previous filing in this sequence was filed on 17 Jun 2022.
Current net transaction value: +$197,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENZ transaction

Common Stock, $0.01 Par Value

Purchase

Transaction value: $197,000
Shares: +100,000
Change %: +36%
Price: $1.97
Shares after: 374,600
Date: 23 Nov 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENZ transaction Derivative

Stock Option (to acquire Common Stock)

Award

Transaction value: $0
Shares: +300,000
Change %
Price: $0.000000
Shares after: 300,000
Date: 23 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $1.97
Footnotes: F2

ENZ holding Derivative

Stock Option (to acquire Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 700,000
Date: 23 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 700,000
Exercise price: $3.39
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Reporting Person was granted Restricted Stock Units that will vest in three equal installments, beginning on November 23, 2023.

Footnote F2

The Reporting Person was granted 300,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 23, 2023.

Footnote F3

The Reporting Person was granted 700,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 8, 2022.